Hexarelin Research for Cardioprotection
An evidence-based overview of research examining Hexarelin in the context of cardioprotection. This page synthesizes findings from peer-reviewed literature.
Research Summary
Hexarelin exhibits unique cardioprotective effects via CD36 receptor binding, independent of GH release. Animal studies showed 40% reduction in infarct size. Human studies demonstrated improved LVEF before GH peak. This GH-independent cardiac benefit distinguishes hexarelin from other GHRPs.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Hexarelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.